The Directory of Pharma Companies and News
Pharmaleads has two products in clinical development which are targeting four multi-billion markets:
PL265 is being developed for the treatment of neuropathic pain (oral) and ocular pain/dry eye syndrome (eye drops). PL37 is being developed for the treatment of post-surgical /breakthrough cancer pain as a substitute of injectable opiates (IV) and acute migraine pain (oral route) Pharmaleads was founded in 2000. It is headquartered in Paris, France, and is funded by Private investors.